GSK plc (GLAXF)
OTCMKTS
· Delayed Price · Currency is USD
18.67
+0.03 (0.17%)
Jun 27, 2025, 3:28 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
HIV | 7.19B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
HIV Growth | 9.12% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg1 | -31.53B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg1 Growth | 2.57% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Meningitis | 1.49B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Meningitis Growth | 16.34% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Influenza | 396.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Influenza Growth | -21.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Established Vaccines | 3.30B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Established Vaccines Growth | 0.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Shingles | 3.29B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Shingles Growth | -7.64% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology | 1.55B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology Growth | 78.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Respiratory, Immunology and Inflammation | 3.47B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Respiratory, Immunology and Inflammation Growth | 13.37% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Respiratory | 7.20B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Respiratory Growth | 6.12% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other General Medicines | 3.15B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other General Medicines Growth | -5.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Commerical Operations | 31.53B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Commerical Operations Growth | 2.57% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pandemic | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pandemic Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pandemic Vaccines | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pandemic Vaccines Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
Commercial Operations Segment Profit | 15.40B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Commercial Operations Segment Profit Growth | 1.74% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Research & Development Segment Profit | -5.89B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Research & Development Segment Profit Growth | 3.64% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 | -3.32B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 Growth | 349.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
US Revenue | 16.55B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
US Revenue Growth | 2.53% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe | 6.79B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Growth | 4.83% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International | 8.19B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Growth | 0.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|